Terms: = Skin cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Staging
13 results:
1. Mitotic rate in primary melanoma: interobserver and intraobserver reliability, analyzed using H&E sections and immunohistochemistry.
Garbe C; Eigentler TK; Bauer J; Blödorn-Schlicht N; Cerroni L; Fend F; Hantschke M; Kurschat P; Kutzner H; Metze D; Mielke V; Preßler H; Reusch M; Reusch U; Stadler R; Tronnier M; Yazdi A; Metzler G
J Dtsch Dermatol Ges; 2016 Sep; 14(9):910-5. PubMed ID: 27607033
[TBL] [Abstract] [Full Text] [Related]
2. Automated quantification of proliferation with automated hot-spot selection in phosphohistone H3/MART1 dual-stained stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Schmidt H; Steiniche T
Diagn Pathol; 2016 Apr; 11():35. PubMed ID: 27062658
[TBL] [Abstract] [Full Text] [Related]
3. B7-H abnormalities in melanoma and clinical relevance.
Seliger B
Methods Mol Biol; 2014; 1102():367-80. PubMed ID: 24258988
[TBL] [Abstract] [Full Text] [Related]
4. Mitotic rate in melanoma: prognostic value of immunostaining and computer-assisted image analysis.
Hale CS; Qian M; Ma MW; Scanlon P; Berman RS; Shapiro RL; Pavlick AC; Shao Y; Polsky D; Osman I; Darvishian F
Am J Surg Pathol; 2013 Jun; 37(6):882-9. PubMed ID: 23629443
[TBL] [Abstract] [Full Text] [Related]
5. Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma.
Tetzlaff MT; Curry JL; Ivan D; Wang WL; Torres-Cabala CA; Bassett RL; Valencia KM; McLemore MS; Ross MI; Prieto VG
Mod Pathol; 2013 Sep; 26(9):1153-60. PubMed ID: 23558574
[TBL] [Abstract] [Full Text] [Related]
6. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
[TBL] [Abstract] [Full Text] [Related]
7. Immunohistochemical dual staining as an adjunct in assessment of mitotic activity in melanoma.
Ikenberg K; Pfaltz M; Rakozy C; Kempf W
J Cutan Pathol; 2012 Mar; 39(3):324-30. PubMed ID: 22335591
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
J Invest Dermatol; 2012 Apr; 132(4):1247-52. PubMed ID: 22297638
[TBL] [Abstract] [Full Text] [Related]
9. pHH3 immunostaining improves interobserver agreement of mitotic index in thin melanomas.
Schimming TT; Grabellus F; Roner M; Pechlivanis S; Sucker A; Bielefeld N; Moll I; Schadendorf D; Hillen U
Am J Dermatopathol; 2012 May; 34(3):266-9. PubMed ID: 22197861
[TBL] [Abstract] [Full Text] [Related]
10. Useof anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma.
Casper DJ; Ross KI; Messina JL; Sondak VK; Bodden CN; McCardle TW; Glass LF
Am J Dermatopathol; 2010 Oct; 32(7):650-4. PubMed ID: 20559123
[TBL] [Abstract] [Full Text] [Related]
11. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
Vidulich KA; Talpur R; Bassett RL; Duvic M
Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma.
Scarisbrick JJ; Whittaker S; Evans AV; Fraser-Andrews EA; Child FJ; Dean A; Russell-Jones R
Blood; 2001 Feb; 97(3):624-30. PubMed ID: 11157477
[TBL] [Abstract] [Full Text] [Related]
13. Mastocytosis.
Fine J
Int J Dermatol; 1980 Apr; 19(3):117-23. PubMed ID: 6156134
[TBL] [Abstract] [Full Text] [Related]
